- Home
- NVAX vs ECAT Comparison
NVAX vs ECAT Comparison
Compare NVAX & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- ECAT
- Stock Information
- Founded
- NVAX 1987
- ECAT 2021
- Country
- NVAX United States
- ECAT United States
- Employees
- NVAX N/A
- ECAT N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- ECAT Trusts Except Educational Religious and Charitable
- Sector
- NVAX Health Care
- ECAT Finance
- Exchange
- NVAX Nasdaq
- ECAT Nasdaq
- Market Cap
- NVAX 1.3B
- ECAT 1.7B
- IPO Year
- NVAX 1995
- ECAT N/A
- Fundamental
- Price
- NVAX $6.38
- ECAT $16.06
- Analyst Decision
- NVAX Buy
- ECAT
- Analyst Count
- NVAX 5
- ECAT 0
- Target Price
- NVAX $16.60
- ECAT N/A
- AVG Volume (30 Days)
- NVAX 5.5M
- ECAT 278.6K
- Earning Date
- NVAX 08-07-2025
- ECAT 01-01-0001
- Dividend Yield
- NVAX N/A
- ECAT 9.20%
- EPS Growth
- NVAX N/A
- ECAT N/A
- EPS
- NVAX 2.97
- ECAT 2.39
- Revenue
- NVAX $1,254,962,000.00
- ECAT N/A
- Revenue This Year
- NVAX $56.85
- ECAT N/A
- Revenue Next Year
- NVAX N/A
- ECAT N/A
- P/E Ratio
- NVAX $2.12
- ECAT $7.15
- Revenue Growth
- NVAX 25.92
- ECAT N/A
- 52 Week Low
- NVAX $5.01
- ECAT $14.02
- 52 Week High
- NVAX $17.81
- ECAT $17.30
- Technical
- Relative Strength Index (RSI)
- NVAX 44.45
- ECAT 51.41
- Support Level
- NVAX $6.26
- ECAT $15.52
- Resistance Level
- NVAX $6.66
- ECAT $15.98
- Average True Range (ATR)
- NVAX 0.33
- ECAT 0.19
- MACD
- NVAX -0.08
- ECAT -0.04
- Stochastic Oscillator
- NVAX 22.16
- ECAT 40.70
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.